Early antiretroviral therapy (ART) initiation reduces the risk of disease progression and HIV transmission, but data on time from HIV care entry to ART initiation are lacking. Using data from the Medical Monitoring Project (MMP), a population-based probability sample of HIV-infected adults receiving medical care in the United States, we assessed time from care entry to ART initiation among persons diagnosed May 2004–April 2009 and used multivariable Cox proportional-hazards models to identify factors associated with time to ART initiation. Among 1094 MMP participants, 83.9% reported initiating ART, with median time to ART initiation of 10 months. In multivariable models, blacks compared to whites [hazard ratio (HR) 0.82; 95% confidence interval (CI) 0.70–0.98], persons without continuous health insurance (HR 0.82; CI 0.70–0.97), heterosexual women and men who have sex with men compared to heterosexual men (HR 0.66; CI 0.51–0.85 and HR 0.71; CI 0.60–0.84, respectively), and persons without AIDS at care entry (HR 0.37; CI 0.31–0.43) had significantly longer times to ART initiation. Overall, time to ART initiation was suboptimal by current standards and significant disparities were noted among certain subgroups. Efforts to encourage prompt ART initiation should address delays among those without health insurance and among certain sociodemographic subgroups.
Get full access to this article
View all access options for this article.
References
1.
Panel on Antiretroviral Guidelines for Adults and Adolescents. Guidelines for the use of antiretroviral agents in HIV-1-Infected adults and adolescents. Department of Health and Human Services. http://aidsinfo.nih.gov/contentfiles/lvguidelines/adultandadolescentgl.pdf (Last accessed July29, 2014).
2.
WalenskyRP, PaltielAD, LosinaE, et al.Test and treat DC: Forecasting the impact of a comprehensive HIV strategy in Washington DC. Clin Infect Dis, 2010; 51:392–400.
3.
Early initiation of ART produces better clinical outcomes. Clin Infect Dis, 2009; 48:iii.
4.
CohenMS, ChenYQ, McCauleyM, et al.Prevention of HIV-1 infection with early antiretroviral therapy. N Engl J Med, 2011; 365:493–505.
5.
GengEH, HareCB, KahnJO, et al.The effect of a “Universal Antiretroviral Therapy” recommendation on HIV RNA levels among HIV-infected patients entering care with a CD4 count greater than 500/mul in a public health setting. Clin Infect Dis, 2012; 55:1690–1697.
6.
GianellaS, von WylV, FischerM, et al.Effect of early antiretroviral therapy during primary HIV-1 infection on cell-associated HIV-1 DNA and plasma HIV-1 RNA. Antivir Ther, 2011; 16:535–545.
7.
CrystalS, SambamoorthiU, MoynihanPJ, McSpirittE. Initiation and continuation of newer antiretroviral treatments among medicaid recipients with AIDS. J Gen Intern Med, 2001; 16:850–859.
8.
HsuLC, TruongHM, VittinghoffE, ZhiQ, ScheerS, SchwarczS. Trends in early initiation of antiretroviral therapy and characteristics of persons with HIV initiating therapy in San Francisco, 2007–2011. J Infect Dis, 2014; 209:1310–1314.
9.
MehtaSH, KirkGD, AstemborskiJ, GalaiN, CelentanoDD. Temporal trends in highly active antiretroviral therapy initiation among injection drug users in Baltimore, Maryland, 1996–2008. Clin Infect Dis, 2010; 50:1664–1671.
10.
HannaDB, BuchaczK, GeboKA, et al.Trends and disparities in antiretroviral therapy initiation and virologic suppression among newly treatment-eligible HIV-infected individuals in North America, 2001–2009. Clin Infect Dis, 2013; 56:1174–1182.
11.
DHHS. Protection of Human Subjects, US Federal Code Title 45 Part 46. Code of Federal Regulations, 2009.
12.
CDC. Distinguishing Public Health Research and Public Health Nonresearch. In: Services HaH, ed, 2010.
13.
BlairJM, McNaghtenAD, FrazierEL, SkarbinskiJ, HuangP, HeffelfingerJD. Clinical and behavioral characteristics of adults receiving medical care for HIV infection—Medical Monitoring Project, United States, 2007. MMWR Surveill Summ, 2011; 60:1–20.
14.
FrankelMR, McNaghtenA, ShapiroMF, et al.A probability sample for monitoring the HIV-infected population in care in the U.S. and in selected states. Open AIDS J, 2012; 6:67–76.
15.
McNaghtenAD, WolfeMI, OnoratoI, et al.Improving the representativeness of behavioral and clinical surveillance for persons with HIV in the United States: The rationale for developing a population-based approach. PLoS One, 2007; 2:e550.
16.
BlairJM, FaganJL, FrazierEL, et al.Behavioral and clinical characteristics of persons receiving medical care for HIV infection—Medical Monitoring Project, United States, 2009. MMWR Surveill Summ, 2014; 63:1–22.
ShapiroMF, MortonSC, McCaffreyDF, et al.Variations in the care of HIV-infected adults in the United States: Results from the HIV Cost and Services Utilization Study. JAMA, 1999; 281:2305–2315.
22.
CunninghamWE, MarksonLE, AndersenRM, et al.Prevalence and predictors of highly active antiretroviral therapy use in patients with HIV infection in the united states. HCSUS Consortium. HIV Cost and Services Utilization. J Acquir Immune Defic Syndr, 2000; 25:115–123.
23.
HallHI, ByersRH, LingQ, EspinozaL. Racial/ethnic and age disparities in HIV prevalence and disease progression among men who have sex with men in the United States. Am J Public Health, 2007; 97:1060–1066.
24.
Hightow-WeidmanLB, SmithJC, ValeraE, MatthewsDD, LyonsP. Keeping them in “STYLE”: Finding, linking, and retaining young HIV-positive Black and Latino men who have sex with men in care. AIDS Patient Care STDS, 2011; 25:37–45.
25.
ChristopoulosKA, DasM, ColfaxGN. Linkage and retention in HIV care among men who have sex with men in the United States. Clin Infect Dis, 2011; 52:S214–S222.
26.
BeerL, FaganJL, GarlandP, et al.Medication-related barriers to entering HIV care. AIDS Patient Care STDS, 2012; 26:214–221.
27.
GhaniAC, DonnellyCA, AndersonRM. Patterns of antiretroviral use in the United States of America: Analysis of three observational databases. HIV Med, 2003; 4:24–32.
28.
HallHI, FrazierEL, RhodesP, et al.Differences in human immunodeficiency virus care and treatment among subpopulations in the United States. JAMA Intern Med, 2013; 173:1337–1344.
29.
DombrowskiJC, KitahataMM, Van RompaeySE, et al.High levels of antiretroviral use and viral suppression among persons in HIV care in the United States, 2010. J Acquir Immune Defic Syndr, 2013; 63:299–306.
30.
CelentanoDD, GalaiN, SethiAK, et al.Time to initiating highly active antiretroviral therapy among HIV-infected injection drug users. AIDS, 2001; 15:1707–1715.
31.
MagidsonJF, Seitz-BrownCJ, ListhausA, LindbergB, AndersonKE, DaughtersSB. Distress tolerance and use of antiretroviral therapy among HIV-infected individuals in substance abuse treatment. AIDS Patient Care STDS, 2013; 27:518–523.
32.
GagliardoC, MurrayM, SaimanL, NeuN. Initiation of antiretroviral therapy in youth with HIV: A U.S.-based provider survey. AIDS Patient Care STDS, 2013; 27:498–502.
